Nihar Desai
Cardiovascular Disease · New Haven, CTNPI 1700930120
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Amgen at 47.0% of the total. 2025 is the largest year on record at $299,378, 2.2 times the $137,737 reported in 2019. Among cardiovascular disease clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,235 payments — averaging $1099.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$638K
- Boehringer Ingelheim$365K
- AstraZeneca$66K
- Novartis$61K
- Bayer$48K
- Vifor Pharma, Inc.$47K
- plus $132K from 20 others
Across 32 payments — averaging $59,982 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$900K
- Boehringer Ingelheim$888K
- Vifor Pharma, Inc.$69K
- Novartis$61K
What the payments were for
- Consulting fees$499,38737%
- Speaking & faculty fees$677,80450%
- Travel & lodging$153,47611%
- Food & beverage$26,9792%
- Education$400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 735 | $638,178 |
| Boehringer Ingelheim | 236 | $365,370 |
| AstraZeneca | 70 | $66,038 |
| Novartis | 45 | $60,895 |
| Bayer | 31 | $47,812 |
| Vifor Pharma, Inc. | 23 | $47,419 |
| Merck | 21 | $20,337 |
| Eli Lilly | 8 | $19,268 |
| Vifor (international) Ltd. | 10 | $18,307 |
| Vifor Fresenius Medical Care Renal Pharma Ltd. | 5 | $13,053 |
| Pharmacosmos Therapeutics Inc. | 6 | $12,892 |
| Boehringer Ingelheim International GmbH | 12 | $10,171 |
| Heartflow, Inc. | 5 | $6,860 |
| CSL Behring | 3 | $6,802 |
| Novo Nordisk AS | 1 | $5,000 |
| Regeneron Healthcare Solutions, Inc. | 4 | $4,506 |
| Lilly USA, LLC | 2 | $4,214 |
| Sanofi-aventis U.S. LLC | 1 | $2,864 |
| Abbott | 7 | $2,636 |
| Sanofi Pasteur Inc. | 1 | $2,462 |
| Amarin Pharma, Inc. | 1 | $1,800 |
| Johnson & Johnson | 4 | $431 |
| Janssen Scientific Affairs, LLC | 1 | $120 |
| Biotronik Inc. | 1 | $115 |
| Novo Nordisk | 1 | $104 |
| Servier Pharmaceuticals LLC | 1 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$501,454
- FARXIGA$65,218
- JARDIANCE$56,543
- Kerendia$47,457
- Veltassa$39,460
- LEQVIO$38,933
- Monoferric$12,837
- PRADAXA$11,852
- ENTRESTO$8,317
- Korsuva$7,800
- FFRct$6,825
- EVKEEZA$4,422
- MULTAQ$2,864
- CardioMEMS HF System$2,280
- Vascepa$1,800
- VERQUVO$1,635
- XARELTO$518
- EVENITY$470
- Prolia$470
- HeartMate 3 Left Ventricular Dev$168
How this compares
$1,357,685 in reported general payments places this provider in the 95th percentile of 415 cardiovascular disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in New Haven
- Jeffery TestaniNew Haven$546K
- Carlos Mena-HurtadoNew Haven$460K
- John ForrestNew Haven$164K
- Henry WardNew Haven$152K
- Cesia Maria Gallegos KattanNew Haven$101K
- Khurram NasirNew Haven$100K
- Tariq AhmadNew Haven$75K
- Joseph AkarNew Haven$74K
- Hyung ChunNew Haven$67K
- Eric VelazquezNew Haven$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.